Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ).
The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart defects and pulmonary hypertension.
Get the full story at our sister site, Drug Delivery Business News.
The post J&J, Actelion still in talks despite Opsumit failure appeared first on MassDevice.
from MassDevice http://ift.tt/2k8RMES
Cap comentari:
Publica un comentari a l'entrada